Caenorhabditis elegans in Parkinson's disease drug discovery: Addressing an unmet medical need

Richard Nass, Kalpana M. Merchant, Timothy Ryan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

It has been over forty years since dopamine neuron degeneration in the substantia nigra and Lewy body formation within surviving cells were described as the pathological hallmarks of Parkinson's disease (PD). Although research in the intervening decades - particularly in the last twenty-five years - has yielded a variety of robust animal models and invaluable mechanistic insights into PD-associated neuronal dysfunction and cell death, therapeutic agents have not been forthcoming to alter the course of PD. Recently, the screening of experimental therapeutics for PD has been pursued through the use of genetically tractable models, such as the nematode Caenorhabditis elegans. This simple worm remarkably recapitulates the basic cellular and molecular pathways associated with PD, is amenable to facile genetic methods, and through the use of high-throughput screening technologies, provides powerful new opportunities for the in vivo identification of therapeutic targets. In this review we briefly describe the utility that the C. elegans model system may have for PD drug discovery.

Original languageEnglish
Pages (from-to)284-293
Number of pages10
JournalMolecular Interventions
Volume8
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Caenorhabditis elegans
Drug Discovery
Parkinson Disease
Lewy Bodies
Nerve Degeneration
Dopaminergic Neurons
Parkinsonian Disorders
Substantia Nigra
Cell Death
Therapeutics
Animal Models
Technology
Research

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Caenorhabditis elegans in Parkinson's disease drug discovery : Addressing an unmet medical need. / Nass, Richard; Merchant, Kalpana M.; Ryan, Timothy.

In: Molecular Interventions, Vol. 8, No. 6, 01.12.2008, p. 284-293.

Research output: Contribution to journalArticle

@article{7ad883b6792749c3bdd7e93cf6da2947,
title = "Caenorhabditis elegans in Parkinson's disease drug discovery: Addressing an unmet medical need",
abstract = "It has been over forty years since dopamine neuron degeneration in the substantia nigra and Lewy body formation within surviving cells were described as the pathological hallmarks of Parkinson's disease (PD). Although research in the intervening decades - particularly in the last twenty-five years - has yielded a variety of robust animal models and invaluable mechanistic insights into PD-associated neuronal dysfunction and cell death, therapeutic agents have not been forthcoming to alter the course of PD. Recently, the screening of experimental therapeutics for PD has been pursued through the use of genetically tractable models, such as the nematode Caenorhabditis elegans. This simple worm remarkably recapitulates the basic cellular and molecular pathways associated with PD, is amenable to facile genetic methods, and through the use of high-throughput screening technologies, provides powerful new opportunities for the in vivo identification of therapeutic targets. In this review we briefly describe the utility that the C. elegans model system may have for PD drug discovery.",
author = "Richard Nass and Merchant, {Kalpana M.} and Timothy Ryan",
year = "2008",
month = "12",
day = "1",
doi = "10.1124/mi.8.6.6",
language = "English",
volume = "8",
pages = "284--293",
journal = "Molecular Interventions",
issn = "1534-0384",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Caenorhabditis elegans in Parkinson's disease drug discovery

T2 - Addressing an unmet medical need

AU - Nass, Richard

AU - Merchant, Kalpana M.

AU - Ryan, Timothy

PY - 2008/12/1

Y1 - 2008/12/1

N2 - It has been over forty years since dopamine neuron degeneration in the substantia nigra and Lewy body formation within surviving cells were described as the pathological hallmarks of Parkinson's disease (PD). Although research in the intervening decades - particularly in the last twenty-five years - has yielded a variety of robust animal models and invaluable mechanistic insights into PD-associated neuronal dysfunction and cell death, therapeutic agents have not been forthcoming to alter the course of PD. Recently, the screening of experimental therapeutics for PD has been pursued through the use of genetically tractable models, such as the nematode Caenorhabditis elegans. This simple worm remarkably recapitulates the basic cellular and molecular pathways associated with PD, is amenable to facile genetic methods, and through the use of high-throughput screening technologies, provides powerful new opportunities for the in vivo identification of therapeutic targets. In this review we briefly describe the utility that the C. elegans model system may have for PD drug discovery.

AB - It has been over forty years since dopamine neuron degeneration in the substantia nigra and Lewy body formation within surviving cells were described as the pathological hallmarks of Parkinson's disease (PD). Although research in the intervening decades - particularly in the last twenty-five years - has yielded a variety of robust animal models and invaluable mechanistic insights into PD-associated neuronal dysfunction and cell death, therapeutic agents have not been forthcoming to alter the course of PD. Recently, the screening of experimental therapeutics for PD has been pursued through the use of genetically tractable models, such as the nematode Caenorhabditis elegans. This simple worm remarkably recapitulates the basic cellular and molecular pathways associated with PD, is amenable to facile genetic methods, and through the use of high-throughput screening technologies, provides powerful new opportunities for the in vivo identification of therapeutic targets. In this review we briefly describe the utility that the C. elegans model system may have for PD drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=58549095658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549095658&partnerID=8YFLogxK

U2 - 10.1124/mi.8.6.6

DO - 10.1124/mi.8.6.6

M3 - Article

C2 - 19144901

AN - SCOPUS:58549095658

VL - 8

SP - 284

EP - 293

JO - Molecular Interventions

JF - Molecular Interventions

SN - 1534-0384

IS - 6

ER -